Target intelligence / Profile preview

MicroRNA 573 (miR-573)

Target
miR-573
Molecular classification
microRNA, non-coding RNA, small RNA
01

Overview

MicroRNA 573 (miR-573) is a small, non-coding RNA molecule that regulates gene expression post-transcriptionally by binding complementary sequences in target mRNAs, leading to either translational repression or transcript degradation. It belongs to the microRNA class of small regulatory RNAs. MiR-573 acts as a negative regulator of cell proliferation, migration, and invasion—particularly shown in cutaneous squamous cell carcinoma and breast cancer—implying a tumor suppressor function. In endothelial cells, miR-573 expression mitigates endothelial permeability and inflammation (notably during Dengue virus infection) by targeting genes such as ANGPT2 and TLR2. MiR-573 is downregulated in various disease contexts, and its overexpression can reverse pathological changes in vitro. While miR-573 is not a therapeutic target like receptors or enzymes, it is considered a regulator or biomarker in research related to cancer, infection, and inflammatory diseases[1][3][5][6][7][9].

Other names
hsa-miR-573MIR573MIRN573mir-573
02

Mechanism of action

MicroRNA 573 binds target mRNAs at the 3' untranslated region (UTR) to suppress translation or promote degradation. It downregulates key targets (e.g., ANGPT2, TLR2). It functions via negatively regulating relevant mRNA expression which affects cellular phenotypes.

03

Biological functions

Negative regulation of cell proliferationNegative regulation of cell migrationNegative regulation of cell invasionRegulation of endothelial permeabilityModulation of inflammatory responsePost-transcriptional gene silencing
04

Disease associations

Cancer (including cutaneous squamous cell carcinoma and breast cancer)Inflammation (including rheumatoid arthritis)Infection (modulates endothelial dysfunction during Dengue infection)
05

Safety considerations

No established safety concerns; therapeutic modulation is experimental, with general miRNA therapeutic issues such as off-target effects and delivery challenges
06

Interacting drugs

None known; agomirs (synthetic miRNA mimics) and antagonists are used in experimental studies but are not drugs in clinical use
07

Biomarkers

Low expression is associated with aggressive cancer phenotypes (used as prognostic biomarker in cancer research)Expression changes in endothelial cells may indicate vascular dysfunction in viral infections

Beyond the preview

Go deeper on MicroRNA 573 (miR-573).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 573 (miR-573).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call